Symbols / VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire Wed, 11 Feb 2026 08
• VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits Mon, 23 Feb 2026 03
• Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week (NASDAQ:VNDA) - Seeking Alpha hu, 19 Feb 2026 13
• Vanda Insider Makes Bold Move With Significant Stock Sale - TipRanks Wed, 25 Feb 2026 03
• What's Going On With Vanda Pharma Stock Tuesday? - Bitget ue, 24 Feb 2026 17
• Vanda Pharmaceuticals surges as FDA approves Bysanti for bipolar I disorder and schizophrenia - Quiver Quantitative Mon, 23 Feb 2026 17
• Vanda Pharmaceuticals (VNDA) Is Up 33.8% After FDA Approval Of BYSANTI Atypical Antipsychotic - simplywall.st ue, 24 Feb 2026 19
• New bipolar and schizophrenia drug builds on 100,000 patient-years of data - Stock Titan Fri, 20 Feb 2026 22
• Stock Movers: Deere, Veris Residential, Vanda Pharmaceuticals - Bloomberg Mon, 23 Feb 2026 16
• Vanda (VNDA) Stock Skyrockets on FDA Approval for Bipolar, Schizophrenia Drug - Tokenist Mon, 23 Feb 2026 12
• US FDA approves Vanda's antipsychotic pill, shares climb - Reuters Fri, 20 Feb 2026 23
• Vanda Pharmaceuticals (VNDA) Stock Rallies 44% as FDA Approves BYSANTI for Bipolar and Schizophrenia - MEXC Mon, 23 Feb 2026 08
• Insider Sell: Tage Honore Sells 30,000 Shares of Vanda Pharmaceu - GuruFocus Wed, 25 Feb 2026 00
• Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy (VNDA) - Seeking Alpha Mon, 23 Feb 2026 19
• New Analyst Forecast: $VNDA Given $24 Price Target - Quiver Quantitative Mon, 23 Feb 2026 12

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 42026-02-24 View
• 8-K2026-02-23 View
• 42026-02-19 View
• 42026-02-19 View
• 42026-02-19 View
• 42026-02-19 View
• 42026-02-19 View
• 8-K2026-02-19 View
• 10-K2026-02-12 View
• 8-K2026-02-11 View
• 8-K2026-01-08 View
• 8-K2025-12-31 View
• 8-K2025-12-04 View
• 8-K2025-11-28 View
• 10-Q2025-10-30 View